Danish medico concern Novo Nordisk, a world leader in diabetes care, has announced in a press release that it is entering a research collaboration with Swedish stem cell biotech company Cellartis and Lund University Stem Cell Center to develop insulin-producing cells from human stem cells. The aim is to create a cell therapy for the treatment of insulin-dependent diabetes and, in the longer term, a cure for diabetes.
The agreement gives Novo Nordisk exclusive rights to further develop and commercialise potential products for treating diabetes, and builds on a long-standing research collaboration between Cellartis and Hagedorn Research Institute, Novo Nordisk’s basic research centre in Denmark.
Professor Henrik Semb, director of Lund University Stem Cell Center and co-founder of Cellartis, says in the press release: "This very important collaboration will strengthen the stem cell research in diabetes at the Lund University Stem Cell Center. I can think of no stronger partner in the area of diabetes than Novo Nordisk."
Mats Lundwall, CEO of Cellartis, commented: "We are delighted that Novo Nordisk has chosen to collaborate with Cellartis in the area of stem cell therapy. It clearly demonstrates that our human embryonic stem cell platform has the potential to achieve clinical breakthroughs in the future."
Headquartered in Denmark, Novo Nordisk is a world leader in diabetes care. The company employs more than 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London.